Options Trading News

March 7, 2013  Thu 2:45 AM CT

Shares of Keryx Biopharmaceuticals have more than doubled in the last six weeks, and one trader apparently thinks that the stock won't return to its earlier levels.

optionMONSTER's tracking systems detected the sale of 5,000 September 4.50 puts in one block for $0.37 yesterday. This is clearly a new position, as open interest in the strike was a mere 62 contracts before the session began.

The put seller will keep the $0.37 credit as profit if KERX stays above $4.50 through expiration in mid-September, around a level where shares traded nearly a year ago. But if the stock falls below that strike price, the trader will face the obligation to buy shares in the drug maker. (See our Education section)

KERX rose 4.34 percent yesterday to close at $7.41, continuing to climb since takeover rumors arose on March 1. The stock skyrocketed from about $3.50 to $9 at the end of January with positive results from Phase III trials for its Zerenex drug, a proposed treatment of abnormally high phosphate levels related to kidney disease.

Overall option volume in the name was about 19,300 contracts yesterday, nearly triple its daily average for the last month.
Share this article with your friends

Related Stories


Trader looks for Keryx to end slide

October 28, 2015

The kidney-treatment developer is down more than 71 percent so far this year after missing revenue expectations for the last three quarters.


Premium Services

Education & Strategy

The art of trading

As I stated in last week's article, a break out or a break down needs to have a couple things happen before it is considered a confirmed break out or break down. The only problem is that in today's market where things move much more quicker than they did just a few years ago, two days could wind up being the majority of the expected movement, if not the whole movement.

View more education articles »